Published in J Pharm Biomed Anal on December 24, 2008
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother (2009) 3.62
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother (2012) 1.88
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis (2012) 1.20
Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother (2010) 1.16
'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis (2012) 1.02
Population pharmacokinetic analysis of colistin in burn patients. Antimicrob Agents Chemother (2013) 0.92
Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal (2014) 0.90
Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob Agents Chemother (2009) 0.89
Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother (2010) 0.88
Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother (2012) 0.88
Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrob Agents Chemother (2015) 0.85
Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin Pharmacokinet (2017) 0.75
Colistin is Extensively Lost during Standard in Vitro Experimental Conditions. Antimicrob Agents Chemother (2017) 0.75
Antibiotic resistance-the need for global solutions. Lancet Infect Dis (2013) 15.01
A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis (2002) 4.61
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Antibiotic resistance in China--a major future challenge. Lancet (2009) 3.09
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med (2006) 2.65
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother (2010) 2.43
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother (2012) 1.88
National campaigns to improve antibiotic use. Eur J Clin Pharmacol (2006) 1.84
Antibiotic resistance--problems, progress, and prospects. N Engl J Med (2014) 1.80
Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother (2008) 1.80
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ (2012) 1.64
Tackling antibiotic resistance. BMJ (2010) 1.60
Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med (2007) 1.58
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care (2010) 1.55
Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. Euro Surveill (2016) 1.48
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother (2005) 1.45
Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Crit Care (2006) 1.41
Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat (2011) 1.40
Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother (2006) 1.39
Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis (2008) 1.37
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother (2006) 1.36
Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care (2006) 1.29
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev (2013) 1.28
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis (2002) 1.20
Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit (2009) 1.19
Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis (2007) 1.15
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother (2011) 1.12
The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol Sci (2010) 1.12
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (2004) 1.10
Severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med (2015) 1.09
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet (2009) 1.07
Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother (2003) 1.06
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol (2012) 1.03
Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. Int J Antimicrob Agents (2011) 1.00
Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother (2004) 0.99
Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother (2003) 0.99
A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res (2009) 0.95
Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother (2011) 0.95
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother (2006) 0.95
Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother (2011) 0.94
Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother (2003) 0.94
Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother (2011) 0.93
Weekly antibiotic prescribing and influenza activity in Sweden: a study throughout five influenza seasons. Scand J Infect Dis (2003) 0.93
Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother (2013) 0.93
Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake. Am J Clin Nutr (2008) 0.92
Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis (2009) 0.92
Genetic polymorphisms within tumor necrosis factor gene promoter region: a role for susceptibility to ventilator-associated pneumonia. Cytokine (2012) 0.92
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol (2013) 0.91
Alcohol-based hand-disinfection reduced children's absence from Swedish day care centers. Acta Paediatr (2008) 0.91
Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother (2007) 0.91
Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother (2005) 0.90
Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother (2003) 0.90
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res (2012) 0.90
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria. Clin Microbiol Infect (1997) 0.89
Performance of nonlinear mixed effects models in the presence of informative dropout. AAPS J (2014) 0.89
Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol (2005) 0.89
Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother (2012) 0.88
Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother (2010) 0.88
High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis (2004) 0.87
Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother (2011) 0.87
Fighting bacterial resistance at the root: need for adapted EMEA guidelines. Lancet Infect Dis (2011) 0.87
Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis (2007) 0.87
Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis (2010) 0.87
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol (2009) 0.86
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res (2013) 0.86
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol (2006) 0.85
Access, excess, and ethics--towards a sustainable distribution model for antibiotics. Ups J Med Sci (2014) 0.85
Reduction in outpatient antibiotic sales for pre-school children: interrupted time series analysis of weekly antibiotic sales data in Sweden 1992-2002. J Antimicrob Chemother (2005) 0.85
Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother (2007) 0.84
A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed (2008) 0.84
Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. J Antimicrob Chemother (2004) 0.84
Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol (2009) 0.84
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol (2015) 0.84
In vitro elution of moxifloxacin and fusidic acid by a synthetic crystallic semihydrate form of calcium sulphate (Stimulan). Int J Antimicrob Agents (2008) 0.84
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs (2010) 0.83
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol (2009) 0.83
Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin. Clin Microbiol Infect (1998) 0.83
Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res (2012) 0.83
A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J Antimicrob Chemother (2014) 0.83